Valneva Announces Start of Phase II Clinical Trial of its Clostridium difficile vaccine candidate
Valneva SE announced the initiation of the Phase II clinical trial of its VLA84 prophylactic vaccine candidate against Clostridium difficile (C. difficile), the main cause of nosocomial diarrhea. Data from the Phase I study in healthy elderly and adults showed good safety and immunogenicity of the vaccine candidate, and indicated functionality of induced antibodies, supporting the Company’s decision to progress the vaccine candidate into Phase II.
The Phase II study (VLA84-201) will enroll 500 healthy subjects aged 50 years and older. This age group represents the target population for a prophylactic C. difficile vaccine as the risk to contract the infection-associated disease increases with age. The randomized, placebo-controlled, observer-blind study will be conducted in Germany as well as in the United States under an Investigational New Drug application (IND). It aims to confirm the optimal dose and formulation of the vaccine in two different age groups and to generate sufficient additional clinical data to advance the program into Phase III.
Valneva expects to announce the first results of the Phase II study at the end of 2015.
Most read news
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Pantothenate_kinase-associated_neurodegeneration
Affimed enrolls first patients in Phase I Hodgkin's Lymphoma Study

Lifespin secures bridge financing - Artificial intelligence to determine health status and diagnose diseases

Price competition for generic drugs linked to increase in manufacturing-related recalls
TranScrip Partners expands further with two new senior appointments - Julia Lloyd-Parks and Mark Watling join the organisation as Senior Partners
Norman-Roberts_syndrome
List_of_subjects_in_Gray's_Anatomy:_III._Syndesmology
What is a laboratory mouse? Jackson, UNC researchers reveal the details

Celonic Inaugurates “Next Generation” Biologics Development Center (BDC) and Pilot Plant in Basel, Switzerland - Reducing the cost and risks of scaling-up biologic medicine production
Intercell announces initiation in the U.S. of a Phase III study for vaccine to protect children against Japanese Encephalitis
